Press Releases Pasithea Therapeutics Corp.

Equities

KTTA

US70261F2020

Delayed Nasdaq Other stock markets 10:34:47 2024-05-06 am EDT			5-day change	1st Jan Change
7.05 ^USD	+1.88%		+1.88%	-4.73%

Apr. 24	Pasithea Therapeutics Corp. Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated Cancers	CI
Mar. 29	Pasithea Therapeutics Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting	Apr. 29	AQ
Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers	Apr. 24	AQ
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004	Feb. 13	AQ
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004, Establishes Strengthened Intellectual Property Position	Jan. 09	AQ
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position	Jan. 08	AQ
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients	Jan. 02	AQ
Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023	Dec. 28	AQ
Pasithea Therapeutics Announces Results from 2023 Annual Meeting	Dec. 19	AQ
Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models	Dec. 11	AQ
Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders	Nov. 29	AQ
Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development	Nov. 29	AQ
Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets 51 Integrin for the Treatment of both Sporadic and Familial ALS	Nov. 10	AQ
Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS	Nov. 09	AQ
Pasithea Therapeutics : Investor Presentation	23-10-13	PU
Pasithea Therapeutics Corp. Announces Final Results of Tender Offer	23-09-14	AQ
Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference	23-09-07	AQ
Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences that shows an increase in 5 integrin expression in ALS human and mouse brain tissue	23-08-02	AQ
Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved survival and motor function	23-08-01	AQ
Pasithea Therapeutics : Failure to Satisfy Listing Rule - Form 8-K	23-07-20	PU
Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash	23-07-20	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Pasithea Therapeutics Corp.

Equities

KTTA

US70261F2020

Press Releases

Filters